anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We will initiate a single arm, open label Phase II study to test the clinical activity of ABT-888 and temozolomide in patients with metastatic colorectal cancer.

Treatment will continue weekly with restaging scans to be performed every 8 weeks. The trial will follow a Simon's two-stage optimal design. For the first stage, 21 patients will be accrued. If two (9.5%) or fewer of the 21 patients exhibit a partial or complete response with ABT-888 plus temozolomide, the agent will be rejected and the trial stopped. However, if at least 3 patients of the 21 (14%) exhibit a response in the first stage, then an additional 29 patients will be entered into the second stage, for a total of 50 patients in this phase II study. If 8 (16%) or more patients exhibit a response, then the treatment will be considered for further investigation. The sample sizes of 21 and 50 patients and the decision rules, in stages 1 and 2 respectively, are designed to differentiate a 25% overall response rate from a 10% overall response rate.
Monitoring of the level of anesthesia has two primary functions: to reduce the incidence of awareness during operation and to avoid too deep anesthesia that is associated with increased risks of mortality and postoperative cognitive impairment. This monitoring can be performed by processed EEG such as "Bispectral Index" that provides a simple interpretation numerical value proportional to the anesthesia level. Nevertheless, "Bispectral index" requires specific tools and disposable material that increases costs for non operating room procedure. Colonoscopy is a non operating room procedure typically performed without or with light sedation, less frequently requires deep sedation. The latter is performed by using Propofol a drug that has a low therapeutic index and might be associated with adverse effects such as respiratory depression, aspiration related to loss of airway reflexes and hypotension. The aim of the present study is to evaluate the reliable interpretation of the raw EEG traces by a staff of digestive endoscopy and operating room for monitoring the level of sedation during non operative room anesthesia to avoid adverse effects.
BACKGROUND: Maternal genetic risk of type 2 diabetes (T2D) has been associated with fetal growth, but the influence of genetic ancestry is not yet fully understood. We aimed to investigate the influence of genetic distance (GD) and genetic ancestry proportion (GAP) on the association of maternal genetic risk score of T2D (GRST2D) with fetal weight and birthweight.
METHODS: Multi-ancestral pregnant women (n = 1,837) from the NICHD Fetal Growth Studies - Singletons cohort were included in the current analyses. Fetal weight (in grams, g) was estimated from ultrasound measurements of fetal biometry, and birthweight (g) was measured at delivery. GRST2D was calculated using T2D-associated variants identified in the latest trans-ancestral genome-wide association study and was categorized into quartiles. GD and GAP were estimated using genotype data of four reference populations. GD was categorized into closest, middle, and farthest tertiles, and GAP was categorized as highest, medium, and lowest. Linear regression analyses were performed to test the association of GRST2D with fetal weight and birthweight, adjusted for covariates, in each GD and GAP category.
RESULTS: Among women with the closest GD from African and Amerindigenous ancestries, the fourth and third GRST2D quartile was significantly associated with 5.18 to 7.48 g (weeks 17-20) and 6.83 to 25.44 g (weeks 19-27) larger fetal weight compared to the first quartile, respectively. Among women with middle GD from European ancestry, the fourth GRST2D quartile was significantly associated with 5.73 to 21.21 g (weeks 18-26) larger fetal weight. Furthermore, among women with middle GD from European and African ancestries, the fourth and second GRST2D quartiles were significantly associated with 117.04 g (95% CI = 23.88-210.20, p = 0.014) and 95.05 g (95% CI = 4.73-185.36, p = 0.039) larger birthweight compared to the first quartile, respectively. The absence of significant association among women with the closest GD from East Asian ancestry was complemented by a positive significant association among women with the highest East Asian GAP.
CONCLUSIONS: The association between maternal GRST2D and fetal growth began in early-second trimester and was influenced by GD and GAP. The results suggest the use of genetic GD and GAP could improve the generalizability of GRS.
TAK-659 40 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 60 mg dose was de-escalated to 40 mg in case of dose limiting toxicity or if the starting dose was determined to be not tolerable. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.
PROBLEM TO BE SOLVED: To obtain a new compound useful for hair cosmetics capable of imparting the hair with excellent wiriness and such favorable feel as not to run slimy or sticky and as to be highly smooth. SOLUTION: This new compound is a compound of the formula [R1 is a 2-30C hydrocarbon; R2 to R5 are each H or a group CH2CH(OH)R1], e.g. N-(2- hydroxyoctadecyl)guanidine. The compound of the formula is obtained, for example, by reaction of guanidine with an α-olefin epoxide (e.g. epoxyoctadecane) in a polar aprotic solvent such as t-butyl alcohol pref. at 0-100 deg.C, This compound is useful as a compounding ingredient for hair cosmetics including hair rinse and hair conditioners.
INTRODUCTION: MicroRNAs (miRNAs) are single RNA molecules that act as global regulators of gene expression in mammalian cells and thus constitute attractive targets in treating cancer. Here we aimed to investigate the possible involvement of miRNA-141 (miR-141) in cervical cancer and to identify its potential targets in cervical cancer cell lines.
METHODS: The level of miR-141 in HeLa and C-33A cells has been assessed using the quantitative real-time PCR (qRT-PCR). A new miR-141 construct has been performed in a CMV promoter vector tagged with GFP. Using microarray analysis, we identified the potentially regulated genes by miR-141 in transfected HeLa cells. The protein profile of killer-like receptor C1 (KLRC1), KLRC3, carcinoembryonic antigen-related cell adhesion molecule 3 (CAM3), and CAM6 was investigated in HeLa cells transfected with either an inhibitor, antagonist miR-141, or miR-141 overexpression vector using immunoblotting and flow cytometry assay. Finally, ELISA assay has been used to monitor the produced cytokines from transfected HeLa cells.
RESULTS: The expression of miR-141 significantly increased in HeLa and C-33A cells compared to the normal cervical HCK1T cell line. Transfection of HeLa cells with an inhibitor, antagonist miR-141, showed a potent effect on cancer cell viability, unlike the transfection of miR-141 overexpression vector. The microarray data of HeLa cells overexpressed miR-141 provided a hundred of downregulated genes, including KLRC1, KLRC3, CAM3, and CAM6. KLRC1 and KLRC3 expression profiles markedly depleted in HeLa cells transfected with miR-141 overexpression accompanied by decreasing interleukin 8 (IL-8), indicating the role of miR-141 in avoiding programmed cells death in HeLa cells. Likewise, CAM3 and CAM6 expression reduced markedly in miR-141 transduced cells accompanied by an increasing level of transforming growth factor beta (TGF-β), indicating the impact of miR-141 in cancer cell migration. The IntaRNA program and miRWalk were used to check the direct interaction and potential binding sites between miR-141 and identified genes. Based on this, the seeding regions of each potential target was cloned upstream of the luciferase reporter gene in the pGL3 control vector. Interestingly, the luciferase activities of constructed vectors were significantly decreased in HeLa cells pre-transfected with miR-141 overexpression vector, while increasing enormously in cells pre-transfected with miR-141 specific inhibitor.
CONCLUSION: Together, these data uncover an efficient miR-141-based mechanism that supports cervical cancer progression and identifies miR-141 as a credible therapeutic target.
The perioperative period presents a unique window of therapeutic opportunities to counteract minimal residual growth and dormancy escape of cancer cells. The main physiological disturbances induced by the surgery, that enhance the tumoral growth in the perioperative period, are due to the neuronal and inflammatory signaling.

We propose a therapeutic modelling of the inflammatory and neurological pathways in a phase II trial using ketorolac and pregabalin, alone or in combination. Ketorolac, a non-selective NSAIDs will target cyclooxygenase (COX)-enzymes, while pregabalin, an anti-epileptic drug will regulates the release of neurotransmitters. Moreover, both drugs have an effect on the postoperative pain and pregabalin has anxiolytic property. Thanks to this study, and through specific blockade, we want to understand how nervous and inflammatory systems remodel the tumour and systemic characteristics. To ensure an integrative analysis of those factors, patient's adiposity as well as other confounding variable will be taken into account.
A 12-year-old Saluki was presented with acute lameness and plantar swelling of the right metatarsus following an episode of free running. Radiographs showed soft tissue swelling only, the involved bone and joint structures were unremarkable. The lesion recurred several months later. Ultrasonographic imaging of the lesion revealed a well-vascularized cavernous structure. Subsequent surgical removal and histopathological examination of the structure raised the initial suspicion of an arteriovenous fistula, which was then confirmed histologically following a second surgical removal of another recurrence. The purpose of this case report is to illustrate the potential complexity of what initially appears to be a simple lameness. At the same time, attention is focused on the possibility that arteriovenous fistulas may tend to recur.
The invention discloses a cluster mallow fruit superfine powder chewable tablet which is prepared from the following components in parts by weight: 40 to 50 parts of cluster mallow fruit, 20 to 30 parts of pericarpium citri reticulatae, 10 to 15 parts of fructus oryzae germinatus, 5 to 10 parts of lotus leaves, 5 to 10 parts of bulbus fritillariae ussuriensis, 5 to 10 parts of smoked plum, 5 to 10 parts of flos farfarae, 5 to 10 parts of licorice root, 5 to 10 parts of microcrystalline cellulose, 1 to 5 parts of mannitol, 1 to 5 parts of polyvinylpyrrolidone and 5 to 10 parts of 95% ethyl alcohol. The invention further discloses a preparation method of the cluster mallow fruit superfine powder chewable tablet. The method comprises the following steps of preparing the superfine powder, pelleting, tableting and the like. The chewable tablet is good in taste, natural, high in nutrition and easy to absorb, and has functions of regulating qi-flowing for strengthening spleen, invigorating stomach for aiding digestion, inducing diuresis for treating stranguria and clearing heat for detumescence. In addition, the application of corrigents is reduced. Thus, the chewable tablet conforms to the development tendency of nutrient, natural and healthy foods. The chewable tablet is suitable for common people to eat in a long term or special people to eat.
The efficacy of PAXIL as a treatment for major depressive disorder (MDD) has been established in 6 placebo‑controlled studies of patients with MDD (aged 18 to 73). In these studies, PAXIL was shown to be statistically significantly more effective than placebo in treating MDD by at least 2 of the following measures: Hamilton Depression Rating Scale (HDRS), the Hamilton depressed mood item, and the Clinical Global Impression (CGI)‑Severity of Illness. PAXIL was statistically significantly better than placebo in improvement of the HDRS sub‑factor scores, including the depressed mood item, sleep disturbance factor, and anxiety factor.

Long-term efficacy of PAXIL for treatment of MDD in outpatients was demonstrated in a randomized withdrawal study. Patients who responded to PAXIL (HDRS total score <8) during an initial 8-week open-label treatment phase were then randomized to continue PAXIL or placebo, for up to 1 year. Patients treated with PAXIL demonstrated a statistically significant lower relapse rate during the withdrawal phase (15%) compared to those on placebo (39%). Effectiveness was similar for male and female patients.
It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure ("the Knack"). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise.
<P>PROBLEM TO BE SOLVED: To obtain a repellent against a pigeon, giving composite repellent effects caused by tactile sense, taste sense and smell sense by appealing to sense organs of the pigeon to effectively prevent the invasion (a harmful action) of the pigeon by coating the repellent, and harmless to a human body.  <P>SOLUTION: This repellent against the pigeon, used by being coated is obtained by adding capsaicin and menthol to an adhesive base obtained by formulating a mineral oil or a grease with a thickener of a carboxylic acid polymer, and kneading the resultant mixture to form a composition. The repellent (composition) of 100 pts. wt. contains the grease (or the mineral oil) of ≤70 pts. wt., the carbomer gel comprising the thickener of the carboxylic acid polymer, a neutralizer and water, of ≤30 pts. wt., and the capsaicin and the menthol of ≤1 pt. wt.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
PURPOSE: The necessity of routine drain placement in pancreatic resections is controversial. Some randomized controlled trials have shown that the omission of drainage is safe for some patients, whereas reintervention rates and mortality rates are substantial for others. The present study aimed to assess fistula-associated outcomes in the setting of routine drain placement and drain irrigation on demand.
METHODS: Between 01/2017 and 12/2022, perioperative and outcome data from patients who underwent consecutive pancreatoduodenectomies (PD, n = 253) or distal pancreatectomies (DP, n = 72) were prospectively collected in the electronic StuDoQ database and analysed. All patients underwent intraoperative drain placement. Drains were removed starting at postoperative day 2 in PD or at day 5 in DP after testing for amylase concentration. In case of high amylase levels or macroscopically suspicious pancreatic fistulas, drain irrigation was started. Nondrained fluid collections underwent percutaneous radiologic or transluminal endoscopic evacuation.
RESULTS: Clinically relevant pancreatic fistulas were detected in 53 of 325 patients (POPF grade B 16.3%, grade C 1.2%). 43.3% of those had drain irrigation. Additional interventional or endoscopic drainage was necessary in 14 and 5 patients, respectively (overall 5.8%), and were observed in 4.0% of patients with PD and in 12.5% with DP (p = 0.009). Delayed fistula-associated postpancreatectomy haemorrhage (PPH) was present in 1.2% (4/325) of patients. The fistula- and delayed PPH-associated reoperation rate was 1.5% (5/325). The 30-day and in-hospital mortality rates were both 1.5% (5/325), and the rate of fistula-associated mortality was 0.6% (2/325). The overall 90-day mortality rate was 4.5%.
CONCLUSIONS: In pancreatectomies, a standardized drainage protocol including on-demand drain irrigation results in very low fistula-associated morbidity and mortality and an infrequent need for interventional or surgical reintervention as compared to previously published drainage studies.
In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
PURPOSE:A skin treating agent, obtained by dispersing and suspending stone powder homogeneously in a polyelectrolytic solution, e.g. a water-absorbing resin solution, reactive with components in sweat to reduce the viscosity thereof, capable of removing horny substance on the skin surface and detecting an accurate potential. CONSTITUTION:A skin treating agent, obtained by dispersing and suspending stone powder homogeneously in a polyelectrolytic solution reactive with components in sweat, e.g. electrolyte such NaCl or lactic acid, to reduce the viscosity thereof and containing the polyelectrolytic solution and the stone powder, and useful for treating the site of the skin for mounting an electrode. A water-soluble resin, e.g. ammonium polyacrylate or Carbopol, water-absorbing resin, e.g. polyacrylic acid based Aquakeep (manufactured by Seitetsu Kagaku Co., Ltd.) may be cited as the polyelectrolytic solution. The agent has a high viscosity when not in use and gives a low viscosity on reaction with the sweat in use and the skin is readily rubbed with simple post-treatment. The horny sybstance can be readily removed and an accurate potential such as electrocardiogram can be detected.
Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
A medical consulting system is disclosed. The medical system includes registration interface, user operation interface, medical personnel operation interface, medical consulting platform and review interface. The registration interface is used to input registration data of the user and the medical personnel. The user operation interface includes user login interface and consulting interface. The medical personnel operation interface includes medical personnel login interface and diagnostic interface. The medical consulting platform includes registration module, consulting module, prescription module, transferring module and payment module. The consulting module connects the consulting interface and the diagnostic interface. The video communication is used to provide the interactive diagnosis. The medication or transferring advice is made according to the consulting result.
The study will include 20 healthy participants of both sexes, aged 18-70 years, that have no clinical suspicion of hypoadrenalism, or any active medical condition or treatment that might alter blood cortisol levels. Pregnant women and patients whose medical or mental condition precludes obtaining informed consent will be excluded.

In the morning of the first visit, 1 mcg of ACTH1-24 will be injected directly into a peripheral vein. Blood and salivary samples will be drawn before injection, and 30 minutes after. Salivary cortisol will be drawn also 60 minutes after injection. At least two days later, in the morning of the second visit, 1 mcg of ACTH1-24 will be injected through short cannula in a peripheral vein, followed by injection of 5 ml of normal saline. Blood and salivary samples will be drawn before injection, and 30 minutes after. Salivary cortisol will be drawn also 60 minutes after injection. Blood cortisol results and salivary free cortisol results will be compared between tests.
Daily headaches sometimes accompany treatment with nitroglycerin. In patients who get these headaches, the headaches may be a marker of the activity of the drug. Patients should resist the temptation to avoid headaches by altering the schedule of their treatment with nitroglycerin, since loss of headache may be associated with simultaneous loss of antianginal efficacy.

Treatment with nitroglycerin may be associated with lightheadedness on standing, especially just after rising from a recumbent or seated position. This effect may be more frequent in patients who have also consumed alcohol.

After normal use, there is enough residual nitroglycerin in discarded patches that they are a potential hazard to children and pets.

A patient leaflet is supplied with the systems.
The present invention provides covalent conjugates between a polypeptide and a modifying group, such as a water-soluble polymer (e.g., PEG). The amino acid sequence of the polypeptide includes one or more O-linked glycosylation sequence, each being a substrate for a GIcNAc transferase. The modifying group is covalently linked to the polypeptide via a glycosyl-linking group interposed between and covalently linked to both the polypeptide and the modifying group. In one embodiment, a glucosamine linking group is directly attached to an amino acid residue of the O-linked glycosylation sequence. The invention further provides methods of making polypeptide conjugates. The present invention also provides non-naturally occurring polypeptides that include at least one O-linked linked glycosylation sequence of the invention, wherein each glycosylation sequence is a substrate for a GIcNAc transferase. The invention further provides pharmaceutical compositions that include a polypeptide conjugate of the invention.
The present invention relates to production of a shampoo composition for preventing hair loss by using an extract of Abeliophyllum distichum Nakai. In the composition, an Abeliophyllum distichum Nakai immersion obtained by immersion-extraction after mixing at least one among flowers, leaves, and branches of Abeliophyllum distichum Nakai is included in 100±5% wt%, and an Abeliophyllum distichum Nakai reflux obtained by reflux-extraction after mixing at least one among flowers, leaves, and branches of Abeliophyllum distichum Nakai is included in 100±5% wt%. Each of the Abeliophyllum distichum Nakai immersion and reflux is included in a weight of about 1-10%, and a shampoo liquid base is included as a remainder in an amount of about 90-99 wt% with respect to the total weight of the composition. Accordingly, active ingredients of an Abeliophyllum distichum Nakai extract can be effectively extracted, and a shampoo composition useful to prevent hair loss can be produced. Thus, by activating antibacterial and antioxidant power, it is possible to effectively clean impurities from the scalp, and to protect the scalp and secure elasticity in damaged pores while keeping hair healthy. Moreover, it is possible to effectively cope with hair loss, weak hair from menopause, or large changes in hair caused by hormonal changes and stress. According to the present invention, effects of preventing hair loss and promoting hair health and hair growth can be provided.